If you appreciate our work, consider supporting us:

QUESTION:

Recent research has shown promising results regarding the use of ketamine and other psychedelics, like psilocybin, in the treatment of certain mental health disorders, such as treatment-resistant depression and PTSD. As future PMHNPs, it's crucial to understand how to evaluate the suitability of patients for these novel treatments.

·       What factors would you consider when determining a patient's appropriateness for ketamine or psychedelic therapies?

·       Discuss both the potential therapeutic benefits and risks.

·       How would you navigate informed consent, and potential contraindications, and integrate these treatments within a broader therapeutic framework?

Moreover, how do societal perceptions and potential stigma regarding these substances play a role in your decision-making and patient education?

ANSWER:

Will answer soon


Back to Questions